Table 6 Clinical characteristics of ACO patients
|  | GOLD [9] (n = 43) | GesEPOC [10] (n = 47) | Soler-Cataluna et al [11] (n = 37) | Marsh et al [6] (n = 46) | Kauppi et al [5] (n = 31) | Louie et al [12] (n = 22) | Rhee [13] (n = 12) | P |
|---|---|---|---|---|---|---|---|---|
Sex (Male) | 26 (60.5%) | 27 (57.4%) | 21 (56.8%) | 36 (78.3%) | 29 (93.5%) | 21 (95.5%) | 10 (71.4%) | P < 0.0001 |
Age,years | 65.72 (9.00) | 65.06 (9.79) | 64.41 (9.74) | 65.46 (9.77) | 65.10 (10.98) | 65.82 (9.37) | 62.58 (10.55) | P > 0.05 |
Duration,years | 10 (1–20) | 10 (5–40) | 10 (5–40) | 5.5 (1.75–15) | 4 (1–12) | 4 (1–12) | 5.5 (1.75–14.25) | P > 0.05 |
Exposures of noxious particles or gases | 28 (65.1%) | 29 (61.7%) | 21 (56.8%) | 39 (84.7%) | 29 (93.5%) | 22 (100%) | 12 (100%) | P < 0.0001 |
EOS,* 10^6/L | 44 (22–200) | 100 (22–286) | 100 (22–260) | 100 (22–205) | 100 (22–200) | 200 (22–273) | 177 (22–215) | P > 0.05 |
IgE,IU/ml | 107 (40–427) | 309 (49.3–647) | 384 (103.1–727.5) | 153 (47.28–470.75) | 138 (34.4–402) | 312.5 (105.75–706.25) | 395 (179.75–996) | P > 0.05 |
IL-2,pg/ml | 539.54 (252.81) | 465.7 (211.6) | 447.57 (198.03) | 533.16 (276.04) | 547.38 (288.53) | 534.30 (242.03) | 546.82 (268.23) | P > 0.05 |
IL-6,pg/ml | 3.26 (2–11.6) | 2.7 (2–5.86) | 2.86 (2–6.33) | 3.45 (2.15–11.6) | 5.86 (2.63–14.35) | 3.33 (2.33–11.83) | 3.14 (2.31–7.63) | P > 0.05 |
IL-8,pg/ml | 21.3 (11.2–66.6) | 17.3 (10.23–32.55) | 16.1 (10.3–33.1) | 19 (11.9–49.1) | 21.7 (12.5–31.55) | 22.2 (10.08–32.63) | 19.9 (9.08–27.7) | P > 0.05 |
TNF,pg/ml | 18 (6.92–23.1) | 12.7 (6.63–22.43) | 13 (6.66–26.1) | 17.2 (8.88–27.5) | 12.3 (8.17–23.7) | 12.5 (8.12–19.85) | 10.2 (6.62–16.4) | P > 0.05 |
Positive results of allergens | 21 (53.8%) | 24 (61.5%) | 20 (69%) | 22 (51.2%) | 11 (42.3%) | 8 (47.1%) | 6 (66.7%) | P > 0.05 |
FEE1/FVC,% | 59.35 (13.90) | 60.95 (14.71) | 59.81 (14.41) | 58.32 (13.70) | 54.57 (11.44) | 56.66 (9.97) | 59.56 (10.93) | P > 0.05 |
FEV1pred,% | 58.95 (22.97) | 59.78 (25.15) | 58.51 (25.08) | 56.19 (23.46) | 50.45 (18.62) | 54.24 (17.78) | 59.59 (20.02) | P > 0.05 |
FVCpred,% | 77 (19.98) | 75.478 (20.08) | 75.318 (20.798) | 73.428 (19.90) | 69.94 (18.10) | 72.46 (16.43) | 76.13 (18.94) | P > 0.05 |
RV/TLC,% | 54.33 (8.84) | 53.34 (7.61) | 53.72 (7.71) | 53.12 (8.04) | 54.65 (7.70) | 54.77 (7.52) | 54.91 (7.84) | P > 0.05 |
FeNO,ppb | 27.91 (26.16) | 42.36 (41.52) | 41.14 (32.01) | 33.61 (31.11) | 28.19 (19.83) | 33.86 (42.30) | 45.92 (54.47) | P > 0.05 |
Increased FEV1% after bronchodilation,% | 13.90 (14.25) | 13.62 (13.67) | 14.85 (15.00) | 17.10 (14.94) | 25.14 (12.66) | 20.69 (12.83) | 20.2 2(14.10) | P < 0.05 |
Increased FEV1 after bronchoditation,ml | 180 (173.95) | 169.79 (154.35) | 180.27 (170.25) | 220.22 (169.20) | 330 (116.56) | 305.45 (134.23) | 325.83 (146.38) | P < 0.0001 |